Home » Stocks » EYPT

EyePoint Pharmaceuticals, Inc. (EYPT)

Stock Price: $9.37 USD -0.22 (-2.29%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 269.31M
Revenue (ttm) 34.44M
Net Income (ttm) -45.39M
Shares Out 28.74M
EPS (ttm) -3.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $9.37
Previous Close $9.59
Change ($) -0.22
Change (%) -2.29%
Day's Open 9.62
Day's Range 9.10 - 9.94
Day's Volume 266,547
52-Week Range 3.51 - 15.06

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -324.44% and -70.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the ...

1 month ago - Zacks Investment Research

WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...

1 month ago - GlobeNewsWire

WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...

1 month ago - GlobeNewsWire

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Stamps.com Inc. (STMP), Ribbon Communications Inc. (RBBN), American Software, Inc. (AMSWA) and E...

Other stocks mentioned: AMSWA, RBBN, STMP
2 months ago - Zacks Investment Research

WATERTOWN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...

2 months ago - GlobeNewsWire

WATERTOWN, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...

2 months ago - GlobeNewsWire

WATERTOWN, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...

2 months ago - GlobeNewsWire

- IND filed in December 2020 for EYP-1901, a potential six-month sustained delivery intravitreal  anti-VEGF treatment targeting wet age-related macular degeneration -

3 months ago - GlobeNewsWire

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up...

Other stocks mentioned: ARGX, GILD, GRCL, INO, LLY, PRTK, ZLAB
3 months ago - Seeking Alpha

WATERTOWN, Mass., Jan. 03, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, to...

3 months ago - GlobeNewsWire

WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative therapeutics to help im...

3 months ago - GlobeNewsWire

WATERTOWN, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, to...

4 months ago - GlobeNewsWire

- No unexpected safety findings during the course of the study -

4 months ago - GlobeNewsWire

WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, to...

4 months ago - GlobeNewsWire

WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, to...

5 months ago - GlobeNewsWire

EyePoint Pharmaceuticals, Inc.'s (EYPT) CEO Nancy Lurker on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -200.00% and 0.22%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the s...

5 months ago - Zacks Investment Research

EyePoint Pharmaceuticals (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, wi...

5 months ago - GlobeNewsWire

WATERTOWN, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, to...

6 months ago - GlobeNewsWire

- Q 3 20 20 net product revenues are estimated to be between $ 5.5 - $ 5.9 million, as healthcare facilities began reopening from COVID-19 closures -

6 months ago - GlobeNewsWire

WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...

7 months ago - GlobeNewsWire

WATERTOWN, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...

7 months ago - GlobeNewsWire

EyePoint Pharmaceuticals (EYPT) news from yesterday concerning a massive deal has EYPT stock continuing to climb higher on Friday. The post EyePoint Pharmaceuticals News: Why EYPT Stock Is Soaring 21% T...

7 months ago - InvestorPlace

WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...

7 months ago - GlobeNewsWire

EyePoint Pharmaceuticals, Inc.'s (EYPT) CEO Nancy Lurker on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 9.09% and 46.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) moved lower by 2.5% in pre-market trading after the company reported Q4 results.

8 months ago - Benzinga

- Total revenues of $4.1 million and net product revenues of $3.7 million impacted by COVID-19 pandemic -

8 months ago - GlobeNewsWire

- Collaboration to bring DEXYCU to ImprimisRx’s established customer base of ophthalmologists, hospitals, and ambulatory surgical centers - - Collaboration to bring DEXYCU to ImprimisRx’s established cu...

8 months ago - GlobeNewsWire

WATERTOWN, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...

8 months ago - GlobeNewsWire

WATERTOWN, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, ...

8 months ago - GlobeNewsWire

- World-renowned retina specialist to lead EYP-1901 development efforts and support expansion of EyePoint’s ocular disease pipeline -

9 months ago - GlobeNewsWire

Despite valuations looking expensive, the markets are in a good place as of this morning, despite the cases for coronavirus spiking over the weekend. Some may say the market is getting ahead of itself.

Other stocks mentioned: BKYI, COCP, EYES, REPH
9 months ago - Forbes

If you’re looking to hedge against a coming pullback in the markets, we've used our deep learning algorithms and AI to identify the Top Shorts today.

Other stocks mentioned: AGEN, ATOM, AXLA, MGEN
9 months ago - Forbes

EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

The market is powering through its third consecutive day of massive gains. Whether the market is too optimistic has been on the minds of many, considering how unstable the economy has been this year.

Other stocks mentioned: BAND, COF, GHSI, HTBX
10 months ago - Forbes

As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks to short to...

Other stocks mentioned: BBI, DGLY, HTBX, MNKD
10 months ago - Forbes

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.00% and 7.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) were flat in pre-market trading after the company reported Q3 results.

11 months ago - Benzinga

EyePoint Still Has A Very Promising Future

1 year ago - Seeking Alpha

- Proactive Efforts to Mitigate Spread and Protect Safety and Well-being of Patients, Treating Physicians, Employees and Our Communities -

1 year ago - GlobeNewsWire

EyePoint Pharmaceuticals' (EYPT) CEO Nancy Lurker on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 25.00% and 12.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

36-month data showed uveitis eye flare recurrence rate of 46.5% in YUTIQ-treated eyes vs. 75.0% in sham eyes, a 40% reduction 36-month data showed uveitis eye flare recurrence rate of 46.5% in YUTIQ-tre...

1 year ago - GlobeNewsWire

EyePoint's stock offering isn't sitting well with shareholders today. Here's why.

1 year ago - The Motley Fool

WATERTOWN, Mass., Feb. 21, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic product...

1 year ago - GlobeNewsWire

  – EYP-1901 combines vorolanib with EyePoint’s bioerodible Durasert™ technology as a six-month sustained release intravitreal therapeutic program to potentially reduce injection frequency of currently ...

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in EyePoint.

1 year ago - Zacks Investment Research

About EYPT

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treat... [Read more...]

Industry
Biotechnology
IPO Date
Jan 27, 2005
Stock Exchange
NASDAQ
Ticker Symbol
EYPT
Full Company Profile

Financial Performance

In 2020, EYPT's revenue was $34.44 million, an increase of 69.10% compared to the previous year's $20.37 million. Losses were -$45.39 million, -20.07% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for EYPT stock is "Buy." The 12-month stock price forecast is 19.25, which is an increase of 105.44% from the latest price.

Price Target
$19.25
(105.44% upside)
Analyst Consensus: Buy